Skip to main content

ADVERTISEMENT

Lawrence J. Green, MD, FAAD

Commentary
08/23/2019
Lawrence Green, MD, shares his perspective on a recent article that showed step therapy and prior authorizations negatively impacted patient care and treatment adherence.  
Lawrence Green, MD, shares his perspective on a recent article that showed step therapy and prior authorizations negatively impacted patient care and treatment adherence.  
Lawrence Green, MD, shares his...
08/23/2019
The Dermatologist
NPF Endorsed Features
09/24/2018
This article discusses the latest evidence on oral molecules for the treatment of psoriasis and psoriatic arthritis.
This article discusses the latest evidence on oral molecules for the treatment of psoriasis and psoriatic arthritis.
This article discusses the...
09/24/2018
The Dermatologist
03/10/2022
In this exclusive interview, Board Member Lawrence Green, MD, and American Academy of Dermatology President-Elect Mark Kaufmann, MD, discuss recent billing coding changes and what dermatologists need to know about the changes in 2022.
In this exclusive interview, Board Member Lawrence Green, MD, and American Academy of Dermatology President-Elect Mark Kaufmann, MD, discuss recent billing coding changes and what dermatologists need to know about the changes in 2022.
In this exclusive interview,...
03/10/2022
The Dermatologist
Cover Story
02/07/2023
Have you found yourself thinking, “I am interested in running a clinical trial, now what?” Dr Lawrence J. Green answers key questions to get you started on the road to conducting clinical trials in the office.
Have you found yourself thinking, “I am interested in running a clinical trial, now what?” Dr Lawrence J. Green answers key questions to get you started on the road to conducting clinical trials in the office.
Have you found yourself...
02/07/2023
The Dermatologist
Advances in Psoriasis Therapies
08/13/2020
  The psoriasis treatment landscape keeps changing for the better, with newer injectable and topical therapies available for patients with mild, moderate, and severe disease. Within the past 2 years alone, the FDA...
  The psoriasis treatment landscape keeps changing for the better, with newer injectable and topical therapies available for patients with mild, moderate, and severe disease. Within the past 2 years alone, the FDA...
...
08/13/2020
The Dermatologist
10/03/2017
In the current managed care environment, it is harder for dermatologists to place their patients on what they feel is the best choice medication for each patient.
In the current managed care environment, it is harder for dermatologists to place their patients on what they feel is the best choice medication for each patient.
In the current managed care...
10/03/2017
The Dermatologist